BofA raises target for AbbVie stock from USD 282.00 to USD 289.00
Published on 10/06/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie (ISIN US00287Y1091) was trading at EUR 236.60 at Lang & Schwarz on October 6, 2026 at 1:06 p.m. CEST, with the price at EUR 236.80 at the prior close. On September 29, 2026, BofA analyst Tim Anderson raised the target for AbbVie from USD 282.00 to USD 289.00 while keeping a Buy rating, Markets Insider reported.
BofA lifts the target to USD 289.00
The revised target gives BofA a concrete bullish marker as AbbVie moves through a period of rapid immunology growth and continuing biosimilar pressure on Humira. The report links the higher valuation to the company's loss-of-exclusivity profile, investment in immunology and neuroscience, and the late-stage pipeline strengthened by recent acquisitions.
The target change followed a strong second-quarter operating picture. AbbVie reported USD 16.99 billion in revenue for Q2 2026, up 10.20 percent from USD 15.42 billion in Q2 2025, while diluted earnings per share reached USD 2.03 compared with USD 0.52 a year earlier, according to Ticker Scout citing AbbVie's Q2 2026 filing.
Skyrizi and Rinvoq offset Humira
Product mix explains why the revenue comparison matters. Skyrizi generated USD 5.51 billion in Q2 2026, up 24.50 percent year over year, while Rinvoq revenue reached USD 2.53 billion, up from USD 2.03 billion in Q2 2025. Humira revenue declined to USD 756.00 million from USD 1.18 billion.
AbbVie also reported USD 3.62 billion in Q2 2026 net income, compared with USD 941.00 million in Q2 2025. The sharp profit increase included lower charges below operating income, so revenue growth and the performance of the newer immunology medicines remain the cleaner indicators of ongoing momentum.
Stock stays below its yearly high
On the NYSE, AbbVie closed at USD 265.76 on October 5, 2026. The primary-exchange 52-week range was USD 190.75 to USD 269.39, leaving the close USD 3.63 below the high, while the Lang & Schwarz euro quote offers the relevant German-market reference.
AbbVie was trading at EUR 236.60 at Lang & Schwarz on October 6, 2026 at 1:06 p.m. CEST, minus 0.08 percent versus the prior close of EUR 236.80. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- WKN: A1J84E
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 6, 2026, 1:06 p.m. CEST: EUR 236.60
- Change versus prior close: minus 0.08 percent
- Prior close Lang & Schwarz September 30, 2026: EUR 236.80
- Market capitalization: USD 469.5 billion (as of October 5, 2026)
- 52-week range: USD 190.75-269.39 (as of October 5, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500
